Picture loading failed.

Anti-EGFR therapeutic antibody (Pre-made Tomuzotuximab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Tomuzotuximab (previously known as CetuGEX) is a novel immune-enhanced monoclonal antibody (mAb) against the epidermal growth factor receptor (EGFR). It is a glycoengineered second generation antibody of cetuximab produced in the human GlycoExpress expression system (Glycotope).

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-586-1mg 1mg 3090
GMP-Bios-ab-586-10mg 10mg 21890
GMP-Bios-ab-586-100mg 100mg 148000
GMP-Bios-ab-586-xmg >100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-EGFR therapeutic antibody (Pre-made Tomuzotuximab biosimilar,Whole mAb)
INN Name Tomuzotuximab
FormatWhole mAb
DerivationChimeric (Mouse/Human)
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI Structure6au5:DC:BA/6axp:BA:DC/6ayn:BA:DC/6azk:DC:BA/6azl:BA:DC/5i76:DC:BA/1yy8:DC:BA/5th2:DC:BA/5f88:DC:BA/5hyq:DC:BA/5ir1:DC:BA/5ivz:DC:BA/5iv2:DC:BA/5t1k:DC:BA/5t1l:DC:BA/5id0:DC:BA/5id1:DC:BA/5euk:DC:BA/5ff6:DC:BA/5iop:DC:BA/5icy:DC:BA/5itf:DC:BA/5etu:DC:BA/5t1m:DC:BA/5esq:DC:BA/5icz:DC:BA/5i2i:DC:BA/5icx:DC:BA/5hpm:DC:BA/4gw5:DC:BA/4gw1:DC:BA/1yy9:DC/4krp:DC/4kro:DC
95-98% SI Structure5gz0:BA:DC/6arp:BA:DC/6aru:CB
Year Proposed2016
Year Recommended2017
Conditions Approvedna
Conditions ActiveHead and neck cancer;Colorectal cancer;Gastric cancer;Non-small cell lung cancer;Renal cancer;Solid tumours
Conditions Discontinuedna
Development TechGlycoExpress Technology